Sari Pesonen | Head Of R&D, Co-Founder
Valo Therapeutics

Sari Pesonen, Head Of R&D, Co-Founder, Valo Therapeutics

Sari Pesonen gained her PhD in biology from the University of Turku, Finland in 2007. She continued her academic career at the University of Helsinki and was awarded a three-year post-doctoral research post by the Academy of Finland. Sari is a co-author in 60+ peer-reviewed research papers and inventor of patented adenovirus based cancer immunotherapy currently in multiple Ph2 clinical trials in the US and Europe. She has worked in biotech companies Oncos Therapeutics and Targovax in scientific lead positions before co-founding a Helsinki University spin out company Valo Therapeutics.

Appearances:



Festival of Biologics Day 1 @ 15:00

Unique cancer and anti-infective immunotherapy platforms

  • ValoTx has developed novel, uniquely flexible and broadly applicable immunotherapy platforms targeting multiple disease specific antigens
  • PeptiCRAdis an oncolytic adenovirus based cancer immunotherapy platform entering clinical testing in 2021
  • PeptiVAXis a vaccine platform for infectious disease - preclinical proof of principle data has been generated
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT

back to speakers